• Type:
  • Category:

Carl Zeiss Meditec AG Financial Results Q1 2022 / 23 | Unlocking the Stellar Performance with CEO and CFO

Share

Excerpt

Get ready to unlock the secrets behind Carl Zeiss Meditec’s stellar Q1-2022/23 financial results!

 

Join Markus Weber, CEO, and Justus Felix Wehmer, CFO, as they take you through the numbers and share their insights. Watch the Q1-2022/23 financial presentation by CEO Markus Weber and CFO Justus Felix Wehmer and get the latest updates on the company’s revenue growth, operating results, and future outlook.

 

Carl Zeiss shows strong growth, with revenue up by 14.6% (adjusted for currency effects: +12.1%). Despite the challenging environment, the team has pulled out all the stops to reduce customer delivery times while continuing to invest in future growth.

 

The Ophthalmology and Microsurgery strategic business units contributed to growth, with solid growth rates reported in all regions. However, there was a weaker operating result than the prior year due to higher operating costs and a weaker product mix. But the outlook for the further course of business in 2022/23 remains positive, with the company expecting further market growth and revenue growth to be at least as strong as the market.

 

Carl Zeiss Meditec AG will continue to invest in sales, marketing, and research and development to launch new products and innovations. We can’t wait to see what the future holds for this innovative company!

 

As the CEO himself says, “Our team is pulling out all the stops to reduce delivery time for our customers. At the same time, we are also continuously investing in our future growth.”

 

You want to attend this presentation, available at seat11a!

Company Profile

The Medical Technology activities of ZEISS are bundled under the umbrella of the MDAX- and TecDAX-listed company Carl Zeiss Meditec AG. 

 

With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world in major markets. The company can also exploit the Carl Zeiss group`s powerful global distribution network.

 

Two Pillars of Business & Markets:

The main activities of Carl Zeiss Meditec AG are located in the field of Ophthalmology and Microsurgery

In Ophthalmology, the Company offers mainly products and solutions for the diagnosis and treatment of eye diseases, as well as systems and consumables for cataract, retinal and refractive surgery. 

In Microsurgery the Carl Zeiss Meditec Group provides visualization solutions for minimally invasive surgical treatments.

 

Markets:

The Carl Zeiss Meditec Group has operations all over the world. 

With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world’s most important markets.

 

Milestones & Innovations:

Research and development plays an important role within the Carl Zeiss Meditec Group. 

Our objective is to enable our customers and physicians to continuously improve treatment results through improvements in efficiency and innovative new products

Carl Zeiss Meditec AG

Goeschwitzer Strasse 51-52

Jena 07745, Germany

phone +49 3641 220 116

Resources

Host

Dr. Markus Weber
CEO | Carl Zeiss Meditec AG

Justus Felix Wehmer
CFO | Carl Zeiss Meditec AG

Sebastian Frericks
Head IR | Carl Zeiss Meditec AG

Share

T&C:

This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

More Elevator Pitches

More Company Presentations

Reviews for Carl Zeiss Meditec AG Financial Results Q1 2022 / 23 | Unlocking the Stellar Performance with CEO and CFO

There are currently no reviews for Carl Zeiss Meditec AG Financial Results Q1 2022 / 23 | Unlocking the Stellar Performance with CEO and CFO
Scroll to top